Developments in combination chemotheraphy for colorectal cancer

Matthew Philip Goetz, Axel F Grothey

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In the 5 years, major advances have occurred in the treatment of colorectal cancer. Following a period of over 30 years in which 5-fluorouracil was the only proven treatment for colorectal cancer, survival for patients with metastatic colorectal cancer has nearly doubled following the introduction of irinotecan (Campto®, Aventis) and oxaliplatin (Eloxatin®, Sonofi-Synthelabo). Furthermore, recent studies have demonstrated additional improvements in response and survival when combination chemotherapy drugs are administered with biologic agents that target angiogenesis and tumor growth pathways. The benefit of these newer drugs is now being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil/leucovrin has led to improvements in disease-free survival. Further adjuvant studies are testing the benefit of the addition of biologic therapies to oxaliplatin and irinotecan-based combination chemotherapy.

Original languageEnglish (US)
Pages (from-to)627-637
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume4
Issue number4
StatePublished - Aug 2004

Fingerprint

oxaliplatin
irinotecan
Colorectal Neoplasms
Combination Drug Therapy
Fluorouracil
Biological Therapy
Survival
Biological Factors
Pharmaceutical Preparations
Disease-Free Survival
Therapeutics
Growth

Keywords

  • 5-fluorouracil
  • Bevacizumab
  • Capecitabine
  • Cetuximab
  • Chemotherapy
  • Colorectal cancer
  • Irinotecan
  • Oxaliplatin

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Developments in combination chemotheraphy for colorectal cancer. / Goetz, Matthew Philip; Grothey, Axel F.

In: Expert Review of Anticancer Therapy, Vol. 4, No. 4, 08.2004, p. 627-637.

Research output: Contribution to journalArticle

@article{953e808c4cb540e9bda90f6a65859f21,
title = "Developments in combination chemotheraphy for colorectal cancer",
abstract = "In the 5 years, major advances have occurred in the treatment of colorectal cancer. Following a period of over 30 years in which 5-fluorouracil was the only proven treatment for colorectal cancer, survival for patients with metastatic colorectal cancer has nearly doubled following the introduction of irinotecan (Campto{\circledR}, Aventis) and oxaliplatin (Eloxatin{\circledR}, Sonofi-Synthelabo). Furthermore, recent studies have demonstrated additional improvements in response and survival when combination chemotherapy drugs are administered with biologic agents that target angiogenesis and tumor growth pathways. The benefit of these newer drugs is now being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil/leucovrin has led to improvements in disease-free survival. Further adjuvant studies are testing the benefit of the addition of biologic therapies to oxaliplatin and irinotecan-based combination chemotherapy.",
keywords = "5-fluorouracil, Bevacizumab, Capecitabine, Cetuximab, Chemotherapy, Colorectal cancer, Irinotecan, Oxaliplatin",
author = "Goetz, {Matthew Philip} and Grothey, {Axel F}",
year = "2004",
month = "8",
language = "English (US)",
volume = "4",
pages = "627--637",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Developments in combination chemotheraphy for colorectal cancer

AU - Goetz, Matthew Philip

AU - Grothey, Axel F

PY - 2004/8

Y1 - 2004/8

N2 - In the 5 years, major advances have occurred in the treatment of colorectal cancer. Following a period of over 30 years in which 5-fluorouracil was the only proven treatment for colorectal cancer, survival for patients with metastatic colorectal cancer has nearly doubled following the introduction of irinotecan (Campto®, Aventis) and oxaliplatin (Eloxatin®, Sonofi-Synthelabo). Furthermore, recent studies have demonstrated additional improvements in response and survival when combination chemotherapy drugs are administered with biologic agents that target angiogenesis and tumor growth pathways. The benefit of these newer drugs is now being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil/leucovrin has led to improvements in disease-free survival. Further adjuvant studies are testing the benefit of the addition of biologic therapies to oxaliplatin and irinotecan-based combination chemotherapy.

AB - In the 5 years, major advances have occurred in the treatment of colorectal cancer. Following a period of over 30 years in which 5-fluorouracil was the only proven treatment for colorectal cancer, survival for patients with metastatic colorectal cancer has nearly doubled following the introduction of irinotecan (Campto®, Aventis) and oxaliplatin (Eloxatin®, Sonofi-Synthelabo). Furthermore, recent studies have demonstrated additional improvements in response and survival when combination chemotherapy drugs are administered with biologic agents that target angiogenesis and tumor growth pathways. The benefit of these newer drugs is now being realized in the adjuvant setting, where the addition of oxaliplatin to infusional 5-fluorouracil/leucovrin has led to improvements in disease-free survival. Further adjuvant studies are testing the benefit of the addition of biologic therapies to oxaliplatin and irinotecan-based combination chemotherapy.

KW - 5-fluorouracil

KW - Bevacizumab

KW - Capecitabine

KW - Cetuximab

KW - Chemotherapy

KW - Colorectal cancer

KW - Irinotecan

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=4444262025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444262025&partnerID=8YFLogxK

M3 - Article

C2 - 15270666

AN - SCOPUS:4444262025

VL - 4

SP - 627

EP - 637

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -